It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Centrosomes are the major microtubule organising centres of animal cells. Deregulation in their number occurs in cancer and was shown to trigger tumorigenesis in mice. However, the incidence, consequence and origins of this abnormality are poorly understood. Here, we screened the NCI-60 panel of human cancer cell lines to systematically analyse centriole number and structure. Our screen shows that centriole amplification is widespread in cancer cell lines and highly prevalent in aggressive breast carcinomas. Moreover, we identify another recurrent feature of cancer cells: centriole size deregulation. Further experiments demonstrate that severe centriole over-elongation can promote amplification through both centriole fragmentation and ectopic procentriole formation. Furthermore, we show that overly long centrioles form over-active centrosomes that nucleate more microtubules, a known cause of invasiveness, and perturb chromosome segregation. Our screen establishes centriole amplification and size deregulation as recurrent features of cancer cells and identifies novel causes and consequences of those abnormalities.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 Instituto Gulbenkian de Ciência, Oeiras, Portugal
2 Instituto Gulbenkian de Ciência, Oeiras, Portugal; Laboratorio Nacional de Microscopía Avanzada, Instituto de Biotecnología, Universidad Nacional Autónoma de México (UNAM), Cuernavaca, Morelos, Mexico
3 I3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal; IPATIMUP - Instituto de Patologia e Imunologia Molecular, Universidade do Porto, Porto, Portugal
4 Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; Departamento de Ciências Biomédicas e Medicina, Universidade do Algarve, Faro, Portugal
5 Instituto Gulbenkian de Ciência, Oeiras, Portugal; European Molecular Biology Laboratory, Heidelberg, Germany
6 Instituto Gulbenkian de Ciência, Oeiras, Portugal; I3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal; IPATIMUP - Instituto de Patologia e Imunologia Molecular, Universidade do Porto, Porto, Portugal
7 Instituto Português de Oncologia de Lisboa, Lisbon, Portugal
8 Novartis Institutes for BioMedical Research, Boston, MA, USA
9 Instituto Gulbenkian de Ciência, Oeiras, Portugal; Institut Pasteur de Montevideo, Montevideo, Uruguay
10 Advanced Imaging Facility, Instituto Gulbenkian de Ciência, Oeiras, Portugal
11 Electron Microscopy Facility, Instituto Gulbenkian de Ciência, Oeiras, Portugal
12 Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
13 Dana-Faber Cancer Institute, Boston, MA, USA
14 Dana-Faber Cancer Institute, Boston, MA, USA; Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom